NASDAQ$ETNB
89Bio Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
89bio reported financial results for the first quarter of 2020 and provided a corporate update.
89bio reported a net loss of $10.5 million for the first quarter of 2020. The company's cash and cash equivalents were $85.5 million as of March 31, 2020. Topline results from the Phase 1b/2a NASH trial are expected in the second half of 2020, and the FDA cleared the IND application for SHTG.
- Closed enrollment in Phase 1b/2a trial of BIO89-100 in NASH, with topline results expected in the second half of 2020.
- FDA cleared the IND Application for BIO89-100 in patients with SHTG.
- Released new preclinical data confirming BIO89-100’s mechanism of action via potent FGF receptor agonism.
- Cash and cash equivalents totaled $85.5 million as of March 31, 2020.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro